TrialFuture oncology (London, England)2014

Impact of adding the multikinase inhibitor sorafenib to endocrine therapy in metastatic estrogen receptor-positive breast cancer.

Suleiman Massarweh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.